...
首页> 外文期刊>Expert review of gastroenterology & hepatology >Ulcerative colitis: Prevention of relapse
【24h】

Ulcerative colitis: Prevention of relapse

机译:溃疡性结肠炎:预防复发

获取原文
获取原文并翻译 | 示例
           

摘要

The clinical management of ulcerative colitis (UC) involves first treating the acute symptoms to induce remission, and then successfully maintaining it. Oral 5-aminosalicylic acids are safe and useful for maintaining remission in patients with UC. In terms of adherence, a once-daily form of 5-aminosalicylic acid is superior in maintaining remission as compared with split dosing. Patients at high risk of relapse may be candidates for treatment with thiopurines and/or biologics in the early stages of UC. Calcineurin inhibitors, such as cyclosporine and tacrolimus, are effective for severe, steroid-refractory UC patients. It is suggested that these patients use thiopurines as their maintenance therapy once they achieve remission with calcineurin inhibitors. Recent studies have confirmed that biologics are effective for inducing clinical and endoscopic remission of UC, and thus they may improve long-term prognosis of UC.
机译:溃疡性结肠炎(UC)的临床管理首先涉及治疗急性症状以诱导缓解,然后成功地维持它。口服5-氨基水杨酸对于维持UC患者的缓解是安全且有用的。在依从性方面,与分次给药相比,每日一次的5-氨基水杨酸形式在维持缓解方面更优越。具有高复发风险的患者可以在UC的早期阶段使用硫嘌呤和/或生物制剂进行治疗。钙调神经磷酸酶抑制剂,例如环孢霉素和他克莫司,对重度类固醇难治性UC患者有效。建议这些患者一旦获得钙调神经磷酸酶抑制剂缓解后,将使用硫嘌呤作为维持疗法。最近的研究证实,生物制剂可有效诱导UC的临床和内镜缓解,因此它们可改善UC的长期预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号